95
Participants
Start Date
September 8, 2022
Primary Completion Date
March 31, 2026
Study Completion Date
August 31, 2026
Emicizumab - PK-guided dose reduction
PK-guided dose reduction emicizumab targeted at a Ctrough of 30μg/mL.
Emicizumab - Dosis continuation group
Continue on their current dose regimen
Emicizumab - Dose adjustment group
Adjusted in dosing regimen according to local protocol
RECRUITING
Radboud University Medical Center, Nijmegen
RECRUITING
Maastricht University Medical Center, Maastricht
RECRUITING
University Medical Center Utrecht, Utrecht
RECRUITING
Amsterdam University Medical Center, Amsterdam
RECRUITING
Leids Universitair Medisch Centrum, Leiden
RECRUITING
Erasmus University Medical Center, Rotterdam
RECRUITING
HagaZiekenhuis, The Hague
RECRUITING
University Medical Center Groningen, Groningen
Collaborators (1)
Erasmus Medical Center
OTHER
Amsterdam University Medical Center
OTHER
Leiden University Medical Center
OTHER
Radboud University Medical Center
OTHER
Maastricht University Medical Center
OTHER
University Medical Center Groningen
OTHER
HagaZiekenhuis
OTHER
Dutch Society of Haemophilia Patients
UNKNOWN
Kathelijn Fischer
OTHER